Gear Up for McKesson (MCK) Q3 Earnings: Wall Street Estimates for Key Metrics

Wall Street analysts forecast that McKesson (MCK) will report quarterly earnings of $8.11 per share in its upcoming release, pointing to a year-over-year increase of 4.8%. It is anticipated that revenues will amount to $95.46 billion, exhibiting an increase of 18% compared to the year-ago quarter.The current level reflects an upward revision of 1.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.With that in mind, let's delve into the average projections of some McKesson metrics that are commonly tracked and projected by analysts on Wall Street.The consensus among analysts is that 'Revenue- U.S. Pharmaceutical' will reach $87.37 billion. The estimate indicates a change of +19.6% from the prior-year quarter.According to the collective judgment of analysts, 'Revenue- Prescription Technology Solutions' should come in at $1.37 billion. The estimate indicates a year-over-year change of +13.5%.Analysts forecast 'Revenue- International' to reach $3.88 billion. The estimate suggests a change of +6.7% year over year.The average prediction of analysts places 'Revenue- Medical-Surgical Solutions' at $3.14 billion. The estimate indicates a change of +3.7% from the prior-year quarter.Analysts expect 'Adjusted Operating Profit- U.S. Pharmaceutical' to come in at $932.05 million. The estimate is in contrast to the year-ago figure of $828 million.The collective assessment of analysts points to an estimated 'Adjusted Operating Profit- International' of $124.60 million. The estimate is in contrast to the year-ago figure of $105 million.It is projected by analysts that the 'Adjusted Operating Profit- Prescription Technology Solutions' will reach $240.56 million. The estimate compares to the year-ago value of $193 million.Based on the collective assessment of analysts, 'Adjusted Operating Profit- Medical-Surgical Solutions' should arrive at $325.11 million. Compared to the current estimate, the company reported $282 million in the same quarter of the previous year.View all Key Company Metrics for McKesson here>>>Shares of McKesson have demonstrated returns of +6.8% over the past month compared to the Zacks S&P 500 composite's +2.9% change. With a Zacks Rank #3 (Hold), MCK is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks